Marizomib: Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier

JBJ-09-063 : Retreatment With EGFR-Tyrosine Kinase Inhibitor After Disease Progression Following Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant Stage III Non-small Lung Cancer: An Efficacy and Safety Analysis of the LOGIK0902/OLCSG0905 Study